AnaCardio AB
- Biotech or pharma, therapeutic R&D
AnaCardio AB is a privately held Swedish clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet, showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program, AC01, an oral ghrelin peptidomimetic small-molecule, is being developed as a contractile agent in heart failure patients.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}